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Down syndrome or Trisomy 21, is the most commonly occurring genetic disorder that
stems from the failure of ·chromosome 21 to segregate normally during meiosis,
resulting in an individual carrying an extra copy of chromosome 21. The main aims of
this study were to develop a relatively non-invasive prenatal DNA screening method
using maternal blood and to detect mutations on cystathionine J3-synthase (CBS) gene, a
folate pathway gene located on chromosome 21. As an initial step, the presence of
foetal cells and DNA in the maternal blood was firstly determined by foetal
haemoglobin (HbF) staining and polymerase chain reaction (PeR). It was found that
the ratio ofthe nucleated foetal cell to maternal cell increased from 2 in 106 to 3 in 106
and 5 in 106 at the first, second and third trimester, respectively. By using Y
chromosome specific primers, DNA from male foetuses could be detected as early as 6
weeks of gestation in 200 Jil maternal blood obtained from fingertip. This is in line
with the current technology in non-invasive screening methods of foetal aneuploidies
which is focused on detecting Y chromosomal sequences which is impossible to be used
4for female foetus pregnancies. Therefore, the superoxide dismutase 1 (SOD'!) gene
sequence, which is located on the Down Syndrome Critical Region, was used to
overcome this situation by using real-time quantitative PCR The level of SOD1
sequences in maternal blood was found to be significantly elevated in the third trimester
normal pregnancies (mean = 11728 copies/Ill) when compared to the second trimester
(mean = 5705.6 copies/Ill), p<0.OO5 and non-pregnant normal women (mean = 3580.2
copies/Ill), p<O.OOOl. Down syndrome pregnancies have the greatest elevation
compared to all the three trimesters of normal singleton pregnancies and twin
pregnancies,p<0.05. The traditional approach ofprenatal chromosomal diagnosis using
amniotic fluid was found to be cumbersome and time-consuming compared to the
newly developed method. The mutation detection on CBS gene was carried out using
DNA sequencer and denaturing high performance liquid chromatography (DHPLC).
This study revealed that the Down syndrome patients have four mutations, which are in
intron 1 (A9231C), exon 10 (C20628T) and exon 17 (T277%C and C27817T). The
Down syndrome children were found to have the same genotype as their mothers. The
number ofmothers and children having the substitutions in the CBS gene was twice the
number ofmothers and children with normal genotype, suggesting that the mothers who
have these substitutions are at higher risk of having a child with Down syndrome. In
conclusion, non-invasive prenatal diagnosis at first trimester using Y chromosomal
sequence IS feasible for diagnosis of foetal-derived paternally-inherited
polymorphism/mutations or genes. Quantitative analysis using gene associated with a
disorder has a potentially significant advantage over the invasive techniques currently
used widely for prenatal diagnosis. Finally, the discovery of the mutations in the CBS
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gene of Down syndrome patients and mothers will help contribute to new knowledge
and the future studies on the folate pathway genes mutation and occurrence of Down
syndrome. It may also suggest an opportunity to improve public health strategies for
the primary prevention ofDown syndrome.
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Sindrom Down atau trisomi 21, merupakan keabnormalan genetik yang paling biasa
berlaku akibat kegagalan kromosom 21 untuk membahagi secara normal semasa
meiosis, menyebabkan seseorang individu mempunyai tambahan satu kromosom 21.
Objektif-objektif utama kajian ini adalah untuk menghasilkan sebuah teknik
penyaringan prenatal DNA yang tidak merbahaya secara relatif dan juga mengesan
mutasi-mutasi pada gene sistathionin f3-sintase (CBS), satu gen yang terletak di tapak-
jalan folat pada kromosom 21. Sebagai langkah pertama, kehadiran sel-sel dan DNA
janin di dalam darah ibu hamil ditentukan dengan pewarnaan haemoglobin janin (HbF)
dan tindakan rantai polymerase (PCR). Didapati bahawa, nisbah antara sel janin
bemuldeus dengan sel ibu hamil bertambah dari 2 dalam 106 kepada 3 dalam 106 dan 5
dalam 106 masing-masing pada trimester pertama, kedua dan ketiga. Primer-primer
yang spesiftk bagi kromosom Y dapat mengesan DNA dari janin-janin lelaki seawal
enam minggu gestasi dengan menggunakan 200 JlI darah ibu hami! yang diambil dari
hujung jari. Ini adalah sejajar dengan teknologi terkini dalam penyaringan janin
7aneuploidi yang tidak merbahaya yang difokus pada pengesanan jujukan kromosom Y
di mana ianya tidak mungkin dapat digunakan untuk kandungan janin perempuan. Oleh
itu, jujukan gen superoxida dismutase 1 (SOD1), yang berlokasi pada Kawasan Kritikal
Sindrom Down, digunakan untuk mengatasi situasi ini melalui aplikasi kuantitatif masa-
benar PCR. Tahap jujukan SODI dalam darah ibu hamil didapati meningkat secara
ketara pada kehamilan normal trimester ketiga (min = 11728 salinan/fll) apabila
dibandingkan dengan kehamilan normal trimester kedua (min = 5705.6 salinan/fll),
p<0.OO5 dan wanita normal yang tidak hamil (min = 3580.2 salinan/fll), p<O.OOOl.
Kehamilan sindrom Down mempunyai peningkatan yang paling tinggi berbanding
dengan kehamilan tunggal kesemua trimester dan kehamilan kembar, p<0.05.
Diagnosis prenatal kromosom tradisional yang menggunakan cecair amnion didapati
sukar dan mengambillebih masa berbanding dengan teknik bam yang telah dihasilkan.
Penentuan mutasi pada gen CBS dilakukan dengan menggunakan penjujuk DNA dan
"denaturing high performance liquid chromatography" (DHPLC). Kajian ini telah
menunjukkan bahawa pesakit sindrom Down mempunyai empat mutasi, iaitu di dalam
intron 1 (A9231C), exon 10 (C20628T) dan exon 17 (T27796C dan C27817T). Kanak-
kanak sindrom Down didapati mempunyai genotaip yang sarna dengan ibu mereka.
Bilangan ibu dan anak yang mempunyai substitusi ini adalah dua kali ganda daripada
ibu dan anak dengan genotaip normal, mencadangkan bahawa ibu yang mempunyai
substitusi ini berisiko tinggi untuk mendapat anak sindrom Down. Sebagai kesimpulan,
diagnosis prenatal yang tidak merbahaya pada trimester pertama menggunakan jujukan
kromosom Y boleh digunakan untuk mendiagnosis janin yang membawa
polimorfisma/mutasi-mutasi atau gen-gen warisan-bapa. Analisis kuantitatif
8menggunakan gen yang berkaitan dengan penyakit mempunyai potensi yang tinggi
berbanding dengan teknik-teknik merbahaya yang digunakan kini secara meluas untuk
diagnosis prenatal. Penemuaan mutasi-mutasi pada gen CBS dalam pesakit sindrom
Down dan ibu mereka akan membantu menyumbangkan pengetahuan barn dan kajian
masa hadapan ke atas mutasi gen-gen di tapak-jalan folat dan kejadian sindrom Down.
Ia juga mungkin memberi peluang untuk memperbaiki strategi kesihatan awam bagi
pencegahan awal sindrom Down.
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CHAPTER I
INTRODUCTION
Chromosomal abnormalities are the most frequent genetic disorders seen in both live
born babies and miscarriages. Down syndrome is a chromosomal abnormality, which
manifests itself in a set of common physical and mental characteristics. This
abnormality is due to the presence of an extra chromosome (chromosome 21). Hence,
the scientific name, trisomy 21.
Most people are aware that the chance ofhaving a baby with Down syndrome is greater
in older women. But Down syndrome can occur at any maternal age. In fact, 75-800.10
of babies with Down syndrome are born in younger women simply because that age
group has more babies (Benke et al., 1995). Studies have proven that inadequate folate
status at the time of conception increases the risk of Down syndrome. Women with
genetic mutations which interfere with the body's ability to absorb folic acid, are at
higher risk for having children with Down syndrome (James et al., 1999).
Down syndrome is a major reason for prenatal diagnosis. Prenatal diagnosis employs a
variety of techniques to determine the heahh and condition of an unborn foetus. Such
diagnosis is usually performed by means of karyotyping and depends on analysis at 11-
18 weeks ofgestation. Karyotyping is not always possible, especially when the number
of cells obtained is limited, where cell culture fails (in 1-2% of patients), or when the
